Granulocyte-Macrophage Colony-Stimulating Factor Gene–Transfected Autologous Tumor Cell Vaccine: Focus on Non–Small-Cell Lung Cancer

Nemunaitis, J.; Nemunaitis, John

doi:10.3816/clc.2003.n.027

Cited by 18 publications

(15 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately 20% of the immunized patients achieved long-term survival in excess of 5 years, in spite of the small number of response according to RECIST criteria [178]. Similarly encouraging results have been reported in non-squamous lung cancer, renal cancer and acute myleogenous leukemia with GM-CSF supplemented autologous tumor cell vaccines [179][180][181][182]. The GVAX approach was also tested on patients with HRPC by vaccinating them with 2 different allogeneic prostate tumor cell lines modified to secrete GM-CSF (see section on Genetic modification of whole tumor cells).…”

Section: Granulocyte-marcophage Colony Stimulating Factormentioning

confidence: 84%

Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines

Chiang

Kandalaft

Coukos

2011

International Reviews of Immunology

View full text Add to dashboard Cite

Whole tumor cell lysates can serve as excellent multivalent vaccines for priming tumor-specific CD8(+) and CD4(+) T cells. Whole cell vaccines can be prepared with hypochlorous acid oxidation, UVB-irradiation and repeat cycles of freeze and thaw. One major obstacle to successful immunotherapy is breaking self-tolerance to tumor antigens. Clinically approved adjuvants, including Montanide™ ISA-51 and 720, and keyhole-limpet proteins can be used to enhance tumor cell immunogenicity by stimulating both humoral and cellular anti-tumor responses. Other potential adjuvants, such as Toll-like receptor agonists (e.g., CpG, MPLA and PolyI:C), and cytokines (e.g., granulocyte-macrophage colony stimulating factor), have also been investigated.

show abstract

Section: Granulocyte-marcophage Colony Stimulating Factormentioning

confidence: 84%

Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines

Chiang

Kandalaft

Coukos

2011

International Reviews of Immunology

View full text Add to dashboard Cite

show abstract

“…On the other hand, GM-CSF can also directly enhance immunogenicity of tumors (Thomas, 2008). In preclinical and clinical studies, the tumor cells genetically engineered to secrete biologically active GM-CSF can generate a systemic antitumor immune response (Tai et al, 2004;Nemunaitis and Nemunaitis, 2003). Analogously, IL-21 is another potent antitumor agent and is a promising candidate for the development of therapeutic tools (Dou et al, 2004;Li and Yee, 2008).…”

Section: Introductionmentioning

confidence: 97%

Antitumor efficacy induced by human ovarian cancer cells secreting IL-21 alone or combination with GM-CSF cytokines in nude mice model

Dou

Wang

et al. 2009

Immunobiology

View full text Add to dashboard Cite

“…A Phase I/II clinical trial using a modified manufacturing process more suited to commercialization of autologous vaccines was conducted in early-and advancedstage NSCLC patients. Results revealed a dose-related survival advantage [111]. A total of 43 patients initiated vaccine treatment (33 with advanced disease), with injections given biweekly for a total of three to six vaccinations.…”

Section: Gvaxmentioning

confidence: 98%

Current vaccine updates for lung cancer

Simmons¹,

Magee²,

Nemunaitis³

2010

Expert Review of Vaccines

Self Cite

View full text Add to dashboard Cite

Current treatments for lung cancer are far from optimal. Several immunotherapeutic strategies involving vaccines incorporating different tumor-associated antigens to induce immune responses against tumors are being tested in clinical trials internationally. Although small, benefits have indeed been observed from the early studies of these vaccines, and the future is looking brighter for lung cancer patients as a handful of these immunotherapies reach Phase III trials. In addition, optimizing the induced immune response by these vaccines has become a priority, and a number of techniques are being considered, including addition of adjuvants and combining vaccines, which affect synergy based on their mechanism of action. This review is an update on the current vaccines in production, the benefits observed from their most recent studies, and the upcoming plans for improvements in these immunotherapies.

show abstract

Granulocyte-Macrophage Colony-Stimulating Factor Gene–Transfected Autologous Tumor Cell Vaccine: Focus on Non–Small-Cell Lung Cancer

Cited by 18 publications

References 111 publications

Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines

Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines

Antitumor efficacy induced by human ovarian cancer cells secreting IL-21 alone or combination with GM-CSF cytokines in nude mice model

Current vaccine updates for lung cancer

Contact Info

Product

Resources

About